Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma

Trial Profile

Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Nov 2013

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Oct 2012 Planned End Date changed from 1 Nov 2010 to 1 Nov 2012 as reported by ClinicalTrials.gov record.
    • 03 Oct 2012 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 01 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top